Novozymes AS
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more
Novozymes AS (NVZMY) - Total Liabilities
Latest total liabilities as of September 2025: $5.58 Billion USD
Based on the latest financial reports, Novozymes AS (NVZMY) has total liabilities worth $5.58 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Novozymes AS - Total Liabilities Trend (2002–2024)
This chart illustrates how Novozymes AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Novozymes AS Competitors by Total Liabilities
The table below lists competitors of Novozymes AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Novozymes A/S B
PINK:NVZMF
|
USA | $5.66 Billion |
|
US Foods Holding Corp
NYSE:USFD
|
USA | $9.64 Billion |
|
China Overseas Land Investment
PINK:CAOVY
|
USA | $483.81 Billion |
|
Ashtead Group plc
PINK:ASHTF
|
USA | $14.65 Billion |
|
CH Robinson Worldwide Inc
NASDAQ:CHRW
|
USA | $3.21 Billion |
|
Legal & General Group Plc
PINK:LGGNY
|
USA | $554.60 Billion |
|
Grupo Cibest S.A.
NYSE:CIB
|
USA | $331.04 Trillion |
|
Bank of Jiangsu Co Ltd
SHG:600919
|
China | CN¥4.64 Trillion |
Liability Composition Analysis (2002–2024)
This chart breaks down Novozymes AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novozymes AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novozymes AS (2002–2024)
The table below shows the annual total liabilities of Novozymes AS from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.02 Billion | -71.37% |
| 2023-12-31 | $14.04 Billion | +2.07% |
| 2022-12-31 | $13.76 Billion | +9.51% |
| 2021-12-31 | $12.56 Billion | +35.56% |
| 2020-12-31 | $9.27 Billion | +3.45% |
| 2019-12-31 | $8.96 Billion | +8.45% |
| 2018-12-31 | $8.26 Billion | +16.23% |
| 2017-12-31 | $7.11 Billion | +2.78% |
| 2016-12-31 | $6.91 Billion | +11.55% |
| 2015-12-31 | $6.20 Billion | -13.27% |
| 2014-12-31 | $7.15 Billion | +31.36% |
| 2013-12-31 | $5.44 Billion | -1.89% |
| 2012-12-31 | $5.54 Billion | +10.50% |
| 2011-12-31 | $5.02 Billion | +5.49% |
| 2010-12-31 | $4.76 Billion | -5.60% |
| 2009-12-31 | $5.04 Billion | -7.52% |
| 2008-12-31 | $5.45 Billion | +4.71% |
| 2007-12-31 | $5.20 Billion | +13.82% |
| 2006-12-31 | $4.57 Billion | +30.07% |
| 2005-12-31 | $3.52 Billion | +8.42% |
| 2004-12-31 | $3.24 Billion | -6.25% |
| 2003-12-31 | $3.46 Billion | -15.70% |
| 2002-12-31 | $4.10 Billion | -- |